Professor Hideto Kojima Presents Biozipcode Research at International Gene Therapy Conference

July 29, 2024 — Professor Hideto Kojima of Shiga University of Medical Science delivered a featured presentation on Biozipcode™ technology at an international conference focused on gene therapy. The session, organized by SLDDDRS and AnGes, gathered more than 20 representatives from key Japanese and U.S. research agencies, including JST, AMED, JSPS, JETRO, NEDO, NICT, NIH, and NSF. Over 50 participants attended from leading universities such as the University of Tokyo, Kyoto University, Nagoya University, Keio University, Academia Sinica, Tohoku University, Stanford, UCSF, UCSD, and the University of Chicago. The conference provided a highly visible platform to introduce Biozipcode’s potential to an audience of global experts, venture capital firms, and policymakers.

Professor Kojima’s presentation, delivered during the Gene Therapy Session, highlighted the promise of Biozipcode™ as a next-generation drug delivery system capable of targeting abnormal stem cells at the root of chronic diseases such as diabetes. He explained how the technology, based on a unique seven–amino acid “postal code,” directs drugs precisely to diseased cells while avoiding healthy tissues. This innovation, which minimizes side effects and maximizes therapeutic efficacy, was presented as a transformative approach to gene therapy with applications extending to diabetes, cancer, and regenerative medicine.

The session also featured leading experts including Professor Masayuki Yamamoto of Tohoku University, Professor Paulmurugan Ramasamy of Stanford, and Professor Matthew Porteus of Stanford, followed by a panel discussion moderated by Dr. Peter N. Kao. Professor Kojima emphasized that Biozipcode™ is uniquely positioned to bridge basic science and clinical application, citing preclinical data and Phase IIa clinical results that demonstrated remission in diabetes models. His talk reinforced the importance of precision drug delivery in making gene therapy safer, scalable, and more effective across different diseases.

In addition to the Gene Therapy Session, Professor Kojima contributed to discussions on university–industry collaboration and presented at the startup-focused sessions, where Biozipcode, Inc. and KIYAN PHARMA Co., Ltd. were introduced to investors and venture capital groups. These engagements not only showcased Biozipcode’s scientific foundation but also underlined its potential as a platform for global innovation. By presenting to an international audience that included policymakers, academics, and investors, Professor Kojima helped position Biozipcode as a pioneering technology with the capacity to redefine therapeutic approaches to some of the world’s most challenging diseases.